Clinical Trial Update: Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations [Phase 2]

View source ↗

Summary

Phase 2 study of Sunvozertinib in untreated advanced non-small cell lung cancer with uncommon EGFR mutations; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Fudan University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: RECRUITING